Investigating why certain brain cells are more vulnerable in Parkinson's Disease
Understanding Cell-type Vulnerability and Oxidative Stress Pathology in Parkinson's Disease Using Isogenic Human Dopaminergic Neurons
This study is looking at how certain brain cells that are important in Parkinson's Disease can be damaged, using special lab-grown cells to see how stress and genes play a role, with the hope of finding new ways to help treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10897131 on NIH RePORTER |
What this research studies
This research focuses on understanding the specific vulnerability of dopaminergic neurons in the brain, which are critically affected in Parkinson's Disease (PD). By using advanced human stem cell models, the study aims to explore the role of oxidative stress and genetic factors that contribute to the degeneration of these neurons. The researchers will utilize CRISPR technology to manipulate genes and observe how these changes affect neuron health and function. This approach seeks to uncover new insights into the mechanisms behind PD and identify potential therapeutic targets for treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's Disease, particularly those with familial forms of the condition.
Not a fit: Patients with other neurodegenerative diseases or those without a diagnosis of Parkinson's Disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Parkinson's Disease by targeting the specific vulnerabilities of affected neurons.
How similar studies have performed: Previous research has shown promise in using CRISPR technology to investigate genetic factors in neurodegenerative diseases, indicating that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Blanchard, Joel William — Icahn School of Medicine at Mount Sinai
- Study coordinator: Blanchard, Joel William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.